By what organ is ivermectin primarily filtered?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ivermectin Renal Filtration and Excretion

Ivermectin is primarily excreted in the feces, with less than 1% of the administered dose excreted in the urine. 1

Pharmacokinetics of Ivermectin

Absorption and Distribution

  • After oral administration, ivermectin plasma concentrations are approximately proportional to the dose 1
  • Following a standard high-fat meal, ivermectin bioavailability increases approximately 2.5-fold compared to administration in the fasted state 1
  • After single 12-mg doses in fasting healthy volunteers, peak plasma concentrations occur at approximately 4 hours after dosing 1

Metabolism

  • Ivermectin is extensively metabolized in the liver 1, 2
  • The primary enzyme responsible for ivermectin metabolism is cytochrome P450 3A4 (CYP3A4) 1, 2, 3
  • CYP3A5 also contributes to ivermectin metabolism but to a significantly lesser extent 2, 3
  • Thirteen different metabolites (M1-M13) have been identified, with three major metabolites (M1, M3, and M6) found in microsomes, hepatocytes, and blood after oral administration 2
  • The main human metabolites are:
    • M1 (3″-O-demethyl ivermectin) - produced primarily by CYP3A4 2
    • M3 (4-hydroxymethyl ivermectin) - produced primarily by CYP3A4 2
    • M6 (3″-O-demethyl, 4-hydroxymethyl ivermectin) - produced primarily by CYP3A4 2

Elimination

  • Ivermectin and/or its metabolites are excreted almost exclusively in the feces over an estimated 12 days 1
  • Less than 1% of the administered dose is excreted in the urine 1
  • The plasma half-life of ivermectin in humans is approximately 18 hours following oral administration 1
  • Some metabolites have longer half-lives than the parent compound, with M1 (54.2 ± 4.7 h) and M4 (57.5 ± 13.2 h) having considerably longer half-lives than ivermectin (38.9 ± 20.8 h) 4

Special Considerations in Specific Populations

Renal Impairment

  • Since ivermectin is primarily eliminated through fecal excretion and minimally through renal excretion, dosage adjustments are not required in patients with renal impairment 5
  • Ivermectin has limited ovicidal activity, and a second dose is often recommended 14 days after the first dose to ensure complete eradication of parasites 5

Hepatic Impairment

  • Patients with severe liver disease may be at higher risk for toxicity as the safety of ivermectin in this population is not well established 6
  • The safety and pharmacokinetics of ivermectin among persons with liver disease have been evaluated only after single-dose administration 5
  • For persons with severe liver dysfunction, caution should be exercised as metabolism may be impaired 6

Mechanism of Action

  • Ivermectin is a member of the avermectin class of broad-spectrum antiparasitic agents 1
  • It binds selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells 1, 7
  • This binding increases the permeability of the cell membrane to chloride ions, causing hyperpolarization of the nerve or muscle cell, resulting in paralysis and death of the parasite 1
  • Ivermectin may also interact with other ligand-gated chloride channels, such as those gated by gamma-aminobutyric acid (GABA) 1, 7
  • The selective activity of ivermectin is attributable to the fact that some mammals do not have glutamate-gated chloride channels and that ivermectin has a low affinity for mammalian ligand-gated chloride channels 1
  • Additionally, ivermectin does not readily cross the blood-brain barrier in humans 1, 7

Clinical Implications

  • Ivermectin should be taken with food to increase bioavailability 5
  • Adjustments to ivermectin dosing are not required in patients with renal impairment 5
  • The safety of multiple doses in patients with severe liver disease is not known 5
  • Ivermectin should not be used in children who weigh less than 15 kg due to potential neurotoxicity 5
  • There is no role for ivermectin in the treatment of CNS infections as it does not reach sufficient concentrations in cerebrospinal fluid 5

In conclusion, ivermectin undergoes extensive hepatic metabolism via CYP3A4 and is primarily eliminated through fecal excretion, with minimal renal excretion.

References

Research

Identification of the metabolites of ivermectin in humans.

Pharmacology research & perspectives, 2021

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Ivermectin Toxicity Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Ivermectin: a mini-review.

Clinical toxicology (Philadelphia, Pa.), 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.